Points to consider regarding the SABR-COMET trial - Authors' reply

David A Palma; Andrew Warner; Suresh Senan

doi:https://doi.org/10.1016/S0140-6736(19)32557-7

Points to consider regarding the SABR-COMET trial - Authors' reply

David A Palma, Andrew Warner, Suresh Senan

Radiation Oncology (VUmc)

Research output: Contribution to journal › Letter › Academic › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	e20
Journal	Lancet
Volume	395
Issue number	10222
DOIs	https://doi.org/10.1016/S0140-6736(19)32557-7
Publication status	Published - 8 Feb 2020

Access to Document

https://doi.org/10.1016/S0140-6736(19)32557-7

http://www.thelancet.com/article/S0140673619325577/pdf

Cite this

@article{a8052f40a0ab4908a9f38cb23845fa31,

title = "Points to consider regarding the SABR-COMET trial - Authors' reply",

author = "Palma, {David A} and Andrew Warner and Suresh Senan",

note = "Funding Information: SS reports grant funding from ViewRay and Varian Medical Systems, and honoraria from AstraZeneca, Celgene, and Merck Sharp & Dohme, outside of the submitted work. DAP and AW declare no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2020",

month = feb,

day = "8",

doi = "https://doi.org/10.1016/S0140-6736(19)32557-7",

language = "English",

volume = "395",

pages = "e20",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10222",

}

TY - JOUR

T1 - Points to consider regarding the SABR-COMET trial - Authors' reply

AU - Palma, David A

AU - Warner, Andrew

AU - Senan, Suresh

N1 - Funding Information: SS reports grant funding from ViewRay and Varian Medical Systems, and honoraria from AstraZeneca, Celgene, and Merck Sharp & Dohme, outside of the submitted work. DAP and AW declare no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/2/8

Y1 - 2020/2/8

UR - http://www.scopus.com/inward/record.url?scp=85078835043&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0140-6736(19)32557-7

DO - https://doi.org/10.1016/S0140-6736(19)32557-7

M3 - Letter

C2 - 32035556

SN - 0140-6736

VL - 395

SP - e20

JO - Lancet

JF - Lancet

IS - 10222

ER -

Points to consider regarding the SABR-COMET trial - Authors' reply

Access to Document

Other files and links

Cite this